Biohaven Advances Late Stage Clinical Programs And Novel Targets

– Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer’s disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019

– Phase 2/3 clinical trial of troriluzole in Alzheimer’s disease has enrolled over 100 patients, enabling the planned futility analysis by end of 2019

– Phase 3 clinical trial of troriluzole in spinocerebellar ataxia is expected to complete enrollment by the first quarter of 2020

– Phase 3 clinical trial of verdiperstat, an oral myeloperoxidase inhibitor, in multiple system atrophy will begin enrollment in third quarter of 2019

– Ongoing non-clinical studies defined under the scientific research agreement with University of Connecticut continue to support the advancement of UC1MT

https://www.prnewswire.com/news-releases/biohaven-advances-late-stage-clinical-programs-and-novel-targets-from-neuroinnovation-platforms-300845918.html